Statements (23)
Predicate | Object |
---|---|
gptkbp:instance_of |
gptkb:immunotherapy
|
gptkbp:administered_by |
oral tablet
|
gptkbp:approves |
gptkb:FDA
|
gptkbp:atccode |
J05 AE05
|
gptkbp:bioavailability |
86%
|
gptkbp:brand |
Reyataz
|
gptkbp:chemical_formula |
C38 H50 N6 O7 S
|
gptkbp:contraindication |
severe liver disease
|
gptkbp:developed_by |
gptkb:Bristol-Myers_Squibb
|
gptkbp:dosage_form |
gptkb:capsule
oral solution |
gptkbp:effective_date |
gptkb:2003
|
https://www.w3.org/2000/01/rdf-schema#label |
atazanavir
|
gptkbp:interacts_with |
gptkb:rifampin
antacids H2-receptor antagonists |
gptkbp:mechanism_of_action |
protease inhibitor
|
gptkbp:side_effect |
headache
nausea diarrhea |
gptkbp:used_for |
treatment of HIV
|
gptkbp:bfsParent |
gptkb:ritonavir
|
gptkbp:bfsLayer |
5
|